Persistent Asset Partners Ltd Buys 17,029 Shares of Urogen Pharma $URGN

Persistent Asset Partners Ltd lifted its stake in Urogen Pharma (NASDAQ:URGN) by 96.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,600 shares of the company’s stock after buying an additional 17,029 shares during the quarter. Persistent Asset Partners Ltd owned about 0.07% of Urogen Pharma worth $474,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Urogen Pharma by 216.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,360,524 shares of the company’s stock worth $48,227,000 after acquiring an additional 2,983,368 shares in the last quarter. RA Capital Management L.P. bought a new position in shares of Urogen Pharma in the first quarter worth approximately $35,461,000. Vestal Point Capital LP increased its stake in shares of Urogen Pharma by 32.1% in the first quarter. Vestal Point Capital LP now owns 2,152,957 shares of the company’s stock worth $23,812,000 after purchasing an additional 522,957 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Urogen Pharma by 607.1% during the 2nd quarter. SG Americas Securities LLC now owns 1,149,081 shares of the company’s stock valued at $15,742,000 after purchasing an additional 986,567 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of Urogen Pharma by 6.3% during the 1st quarter. Parkman Healthcare Partners LLC now owns 393,153 shares of the company’s stock valued at $4,348,000 after purchasing an additional 23,292 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Urogen Pharma

In other Urogen Pharma news, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the completion of the transaction, the chief financial officer directly owned 2,280 shares of the company’s stock, valued at $38,418. This trade represents a 49.14% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the sale, the general counsel owned 43,305 shares in the company, valued at approximately $827,558.55. This trade represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 4,594 shares of company stock valued at $82,813 in the last quarter. 4.70% of the stock is owned by company insiders.

Urogen Pharma Price Performance

NASDAQ URGN opened at $23.76 on Friday. Urogen Pharma has a 1-year low of $3.42 and a 1-year high of $25.19. The business has a 50 day simple moving average of $19.15 and a two-hundred day simple moving average of $15.59. The stock has a market capitalization of $1.11 billion, a PE ratio of -6.87 and a beta of 1.06.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, November 6th. The company reported ($0.69) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.03. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 170.59%.The firm had revenue of $27.48 million during the quarter, compared to the consensus estimate of $34.09 million. On average, analysts anticipate that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

URGN has been the subject of a number of analyst reports. D. Boral Capital reiterated a “buy” rating and issued a $25.00 price target on shares of Urogen Pharma in a research note on Monday, October 27th. HC Wainwright restated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a research report on Monday, October 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Piper Sandler began coverage on Urogen Pharma in a research note on Monday, August 18th. They set an “overweight” rating and a $36.00 target price on the stock. Finally, Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.